Innovative and diverse
The Naissos Group (TNG) is an entrepreneurial, family-owned private investment firm that launches its own innovative ventures and at the same time invests in and partners with companies across an array of industries, with a strong focus in the life sciences. TNG was founded in 2008, and today manages a diversified portfolio of investments that includes wholly-owned companies, stealth-mode ventures, and minority positions in outside investments.
We are entrepreneurs at heart: constantly brainstorming, ideating, and thinking about the next venture that might eventually rock the status quo. One left-brained (Alex), the other right-brained (Mika), our partners don’t always see eye to eye, but when they do, it’s usually the birth of another investment or entrepreneurial venture.
Whether outcompeting established strategy consulting firms with a lean engagement model in which a senior, multidisciplinary team takes an active role, or investing in fine art from a region that receives little attention, we strive to identify unique ways of making an impact and doing things differently.
Most importantly, we aren’t passive investors. When we are a true believers, we roll up our sleeves and become actively involved in the day-to-day management of, or we have a significant advisory role in the ongoing operation of each portfolio company. We want our partners and employees to know that we have a vested interest in each company.
A believer's philosophy.
While Alex maintains an organized workbook of Mika’s ideas for ventures that could solve a problem or address an unrecognized need, this awkward duo retains a certain optimism that one day they will find the bandwidth and resources to further develop at least some of their wild ideas.
family of companies
Started in 2021, Qoolo is our response to current life-science industry gaps and status quo. Still in stealth mode, but on a clear mission to transform how healthcare professionals engage with life-science companies. More to be revealed soon.
The TNG portfolio
Enterin joined our portfolio in 2016. This biotech is at the forefront of understanding the gut-brain axis and its role in neurodegenerative disease. We are excited to be along for the journey. For several years, we have supported Enterin with a range of commercial, communications, and clinical operations services.
Oncolyze joined our portfolio in 2019. We have built a strong interest in the oncolgy therapeutics behind this innovative biotech. We have taken an equity position in Oncolyze and rolled up our sleeves, with Alex acting as Chief Operating Officer and TNG Creative acting as the company’s strategic communications agency.
Avanzarx joined our portfolio in 2021. We have begun our collaboration with this seed-stage biotech that is developing therapeutics to modulate novel or previously unreachable immunological targets for the treatment of inflammatory and fibrotic diseases, initially of the lungs.
alex stojanovic, phd
mika stojanovic, mba
Get in touch
Thank you for visiting our website.
We are passionate entrepreneurs + investors, and we enjoy working with a diverse group of like-minded entrepreneurs, startup teams, and small to mid-sized life-science companies, as well as life-science focused investors, venture capital and private equity firms.
We are located in Princeton NJ, but our portfolio companies, collaborators, and network are global. No matter where you are located, if you think there are synergies or opportunities to work together, reach out.
All rights reserved.